Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma, Large B-Cell, Diffuse

Lymphoma

Lymphoma, B-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

Lymphosarcoma

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Antirheumatic Agents

Etoposide

Cytarabine

Rituximab

Melphalan

Etoposide phosphate

Carmustine

Antineoplastic Agents, Immunological

Immunologic Factors

Enzyme Inhibitors

Antimetabolites

Antiviral Agents

Immunosuppressive Agents

Antineoplastic Agents, Alkylating

Alkylating Agents

Arm 1 BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + Standard Rituximab with Standard Rituximab for Cohort 1 or 2

Cohort 1 for 65 years of age or younger BEAM: Carmustine 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.

Cohort 2 for older than 65 years of age BEAM: Carmustine 300 mg/m2 IV over 1 hour on day -6, cytarabine 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.

Standard Rituximab: 375 mg/m\^2 IV Days +1, +8 after Stem Cell Infusion on Day 0.

BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + High Dose Rituximab

Cohort 1 for 65 years of age or younger BEAM: Carmustine 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.

Cohort 2 for older than 65 years of age BEAM: Carmustine 300 mg/m2 IV over 1 hour on day -6, cytarabine 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.

High Dose Rituximab: 1000 mg/m\^2 IV Days +1, +8 after Stem Cell Infusion on Day 0

Arm 1 = 200 mg/m\^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m\^2 IV Every 12 Hours x 4 Days

Cohort 1, High-Dose Rituximab = 1000 mg/m\^2 IV On Days +1 and +8 After Stem Cell Infusion; Cohort 2, Standard Dose Rituximab = 375 mg/m\^2 IV On Days +1 and +8 After Stem Cell Infusion.

Chitra M. Hosing, MD

Cohort 1: Patients who are less than or equal to 65 years of age.

1. To determine the disease-free survival (DFS) in the 2 arms (standard dose versus high dose rituximab)

Cohort 2: Patients who are older than 65 years of age

1. To determine the disease-free survival (DFS) in the 2 arms (standard dose versus high dose rituximab)
2. To determine the treatment related mortality (TRM)

Carmustine, cytarabine, etoposide, melphalan, and rituximab are all standard chemotherapy drugs.

If you are found to be eligible to take part in this study, you will be randomly assigned (as in the toss of a coin) to one of two treatment groups. Participants in one group will receive high dose rituximab with transplantation and high dose chemotherapy. Participants in the other group will receive standard dose rituximab with transplantation and high dose chemotherapy. The first 10 patients enrolled on this study will have an equal chance of being assigned to either group. After the first 10 participants are enrolled, the remaining participants will have a higher chance of being assigned to the group that has proven to be more effective.

All participants will have a plastic tube (catheter) inserted under their collarbone. This catheter will be left in place for the entire treatment period. The catheter will be used to deliver most of the drugs and for the collection and transfusion of the stem cells. When possible, all drugs that need to be given by vein will be given using the catheter.

Stem cell collection is done on a separate study and patients will take part in this study only after the stem cell collection is complete. You should have an adequate number of stem cells collected and stored before you can be eligible for high-dose chemotherapy and transplantation.

All treatment will be given at M. D. Anderson. You will be admitted to the hospital to receive high dose chemotherapy and will stay in the hospital for 3-4 weeks. You will be given carmustine by vein over 1 hour on Day 1. On Days 2 - 5, you will be given cytarabine by vein over 1 hour and etoposide by vein over 3 hours. This will be repeated every 12 hours on Days 2-5. On Day 6, you will be given melphalan by vein over 30 minutes. On Day 7, the stem cells that were collected earlier will be given back to you ("transplanted") through the catheter over 30-45 minutes.

You will also receive either high dose or standard dose rituximab by vein over 4-6 hours one day after the transplant (Day 1) and then again 1 week later (Day 8).

You will receive G-CSF injections staring at Day 1 (one day after transplant or stem cell infusion). These will continue our cell count reaches the appropriate level for at least 3 days in a row. Blood tests (2 teaspoons) will be done every day while you are in the hospital to track the effects of the transplant.

You will be asked to return to M. D. Anderson at 3 months and 6 months after transplantation, then every 6 months for 3 years, and then once a year up to 5 years from the transplant date. At each visit you will get blood work (1-2 tablespoons), CT scans, and other tests like bone marrow (if needed) to determine the status of your lymphoma.

This is an investigational study. All of the drugs used in this study are FDA approved and are commercially available. Up to 100 patients will take part in this study. All will be enrolled at M. D. Anderson.

Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies

Randomized Trial Using Standard Dose Versus High Dose Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Diffuse Large B Cell Lymphomas

DFS defined as time from transplantation to disease relapse, disease progression, death during remission, or last follow-up. Evaluation at 3 months and 6 months after transplantation, then every 6 months for 3 years, and then once a year up to 5 years from the transplant date.

M.D. Anderson Cancer Center

Arm 2: BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + High Dose Rituximab

Cohort 1 65 Years of Age or Less With Arm 2

Arm 1: BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + Standard Dose Rituximab

Cohort 2 Patients Who Are Older Than 65 Years of Age Arm 1

Cohort 1 65 Years of Age or Less With Arm 1

Cohort 2 Patients Who Are Older Than 65 Years of Age Arm 2

Total

Age, Categorical

Age, Continuous

Sex: Female, Male

United States

Region of Enrollment

Chitra M. Hosing, MD / Associate Professor

Standard dose arm: Rituximab 375 mg/m\^2 intravenous on days +1 and +8 after stem cell infusion.

Standard Dose Rituximab

High dose arm: Rituximab 1000mg/m\^2 intravenous on days +1 and +8 after stem cell infusion

High Dose Rituximab

Disease-free Survival (DFS)

Overall Study

Lymphoma, Non-Hodgkin

Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab

Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant

BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab

BEAM + Rituximab Followed by Stem Cell Transplant

(111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.

Zevalin

Arm 1, Arm 2 = 250 mg/m\^2 by vein;

Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m\^2 by vein following Stem Cell Transplant;

Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.

Stem Cell Transplant

Issa F. Khouri, MD

The goal of this clinical research study is to learn if the addition of 90Y Zevalin to BEAM chemotherapy (carmustine, etoposide, cytarabine, and melphalan) and rituximab is more effective than the combination of BEAM and rituximab alone in patients with lymphoma who receive a stem cell transplant.

The Study Drugs:

90Y Zevalin is designed to attach to lymphoma cells, and destroy the cells using a radiation particle that is attached to it.

111In Zevalin is like 90Y Zevalin, but the radioactive particle that is attached to it does not kill lymphoma cells. The radioactive particle makes the drug able to be seen inside your body. It is being used in this study to predict how fast the study drug will travel in the body and how long the drug stays in the body.

Carmustine, etoposide, cytarabine, and melphalan (BEAM) are designed to kill lymphoma cells by damaging the cells DNA.

Rituximab is designed to attach to lymphoma cells, which may cause them to die.

Study Groups 1 and 2:

If you are found to be eligible to take part in this study, you will be randomly assigned (as in the toss of a coin) to 1 of 2 groups. You will have an equal chance of being assigned to each group. Group 1 will receive 90Y Zevalin along with rituximab and BEAM therapy. Group 2 will receive rituximab and BEAM therapy. You and the study staff will know which group you are in.

Study Drug Administration:

If you are in Group 1, you will receive rituximab through a needle in your vein (over 4-5 hours) followed by 111In Zevalin by vein (over 15 minutes). A nuclear scan will be done within the following 40 to 48 hours to see how the drug is traveling through your body.

If intolerable side effects are not shown by the scans, you will receive rituximab (over 4-5 hours) and 90Y Zevalin (over 15 minutes) through a needle in your vein 7 days after the 111In Zevalin infusion.

You will begin BEAM chemotherapy 7 days after the second 90Y Zevalin infusion.

BEAM Chemotherapy:

Both groups will have 7 days of BEAM combination chemotherapy.

* On Day 1, you will receive carmustine through a needle in your vein over 1 hour.
* On Days 2-5 you will receive cytarabine by vein (over 1 hour) followed by etoposide (over 3 hours). Both infusions will be repeated every 12 hours on Days 2-5.
* On Day 6 you will be given melphalan by vein over 30 minutes.
* On Day 7 the stem cells that were collected earlier from you will be given back ("transplanted") through a catheter over 30-45 minutes.
* You will also receive rituximab by vein (over 5-7 hours) on Day 8.

You will receive rituximab (over 4-5 hours) 7 days after the stem cell transplant. You will receive G-CSF by injection once a day starting 7 days after the stem cell transplant until your blood counts return to a normal level. You should stay in the Houston area for about 2-4 weeks after the transplant.

Study Procedures:

At about 1 month after the transplant you will have x-rays, CT scans, and positron emission tomography (PET) scans. You will also have a bone marrow aspirate and biopsy to check the status of the disease.

Blood (about 1 tablespoon) will be drawn once a day while you are in the hospital to check your blood counts.

Blood tests (about 1-2 tablespoons), urine tests, bone marrow collections, and x-rays may be done as needed to track the effects of the transplant.

You will have transfusions of blood and platelets as needed.

Study Groups A and B:

About 1 month after the transplant, you will be randomly assigned (as in the toss of a coin) to 1 of 2 new groups (Group A and Group B). Group A will receive rituximab by vein over 5-7 hours, once every 3 months, starting 3 months after the stem cell transplant. You will receive rituximab for the first 18 months after the stem cell transplant. Group B will not receive rituximab. You will have an equal chance of being in each group.

Follow-up Visits:

You will return to the clinic every 6 months for 5 years to check the status of the disease. The following tests and procedures will be performed:

* Blood (about 1-2 tablespoons) and urine will be collected for routine tests.
* You will have a bone marrow biopsy to check the status of the disease.
* You will have a chest x-ray and a CT scan.
* You will have a PET scan.

Length of Study:

You may stay on study as long as you are benefitting. You will be taken off-study if the disease gets worse or intolerable side effects occur.

This is an investigational study. 90Y-Zevalin is approved by the FDA for relapsed and refractory lymphoma. Its use in this study is investigational. 111In Zevalin, Carmustine, etoposide, cytarabine, melphalan, and Rituximab are all FDA approved and commercially available. However, their use together in this study is also investigational. Up to 50 patients will be take part in this study. All will be enrolled at MD Anderson.

Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation

Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab Maintenance in Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphomas

Response evaluated using the standard criteria response for lymphoma through CT scan.

Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab

Zevalin: (111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.

Carmustine: 300 mg/m\^2 by vein.

Etoposide: 200 mg/m\^2 by vein every 12 hours.

Cytarabine: 200 mg/m\^2 by vein every 12 hours.

Melphalan: 140 mg/m\^2 by vein.

Rituximab: Arm 1, Arm 2 = 250 mg/m\^2 by vein;

Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m\^2 by vein following Stem Cell Transplant;

Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.

Stem Cell Transplant: Injection of stem cells (Autologous SCT)

Group 1 - Zevalin + BEAM + Rituximab +Stem Cell Transplant

Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant

Zevalin: (111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.

Carmustine: 300 mg/m\^2 by vein.

Etoposide: 200 mg/m\^2 by vein every 12 hours.

Cytarabine: 200 mg/m\^2 by vein every 12 hours.

Melphalan: 140 mg/m\^2 by vein.

Rituximab: Arm 1, Arm 2 = 250 mg/m\^2 by vein;

Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m\^2 by vein following Stem Cell Transplant;

Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.

Stem Cell Transplant: Injection of stem cells (Autologous SCT)

Group 1 - Zevalin + BEAM + Stem Cell Transplant

BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab

Carmustine: 300 mg/m\^2 by vein.

Etoposide: 200 mg/m\^2 by vein every 12 hours.

Cytarabine: 200 mg/m\^2 by vein every 12 hours.

Melphalan: 140 mg/m\^2 by vein.

Rituximab: Arm 1, Arm 2 = 250 mg/m\^2 by vein;

Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m\^2 by vein following Stem Cell Transplant;

Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.

Stem Cell Transplant: Injection of stem cells (Autologous SCT)

Group 2 - BEAM + Rituximab + Stem Cell Transplant

BEAM + Rituximab Followed by Stem Cell Transplant

Carmustine: 300 mg/m\^2 by vein.

Etoposide: 200 mg/m\^2 by vein every 12 hours.

Cytarabine: 200 mg/m\^2 by vein every 12 hours.

Melphalan: 140 mg/m\^2 by vein.

Rituximab: Arm 1, Arm 2 = 250 mg/m\^2 by vein;

Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m\^2 by vein following Stem Cell Transplant;

Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.

Stem Cell Transplant: Injection of stem cells (Autologous SCT)

Group 2 - BEAM + Stem Cell Transplant

Ethnicity (NIH/OMB)

Issa F. Khouri, MD / Stem Cell Transplantation

Number of Participants With a 2-Year Progression-Free Survival (PFS)

Lenograstim

Antibodies

Antibodies, Monoclonal

Immunoglobulins

Rituxan 250 mg/m2 preceding imaging dose of 111In Zevalin (5 mCi); additional infusion 250 mg/m2 Rituxan followed by therapeutic dose of 0.4 mCi/kg 90Y Zevalin received one week after Rituxan/111In Zevalin infusions. One week later, chemotherapy received with BCNU (300 mg/m2, intravenously (IV) day -6) VP-16 (200 mg/m2 IV every 12 hours, days -5 to -2) cytarabine (200 mg/m2 IV every 12 hours, days -5 to -2) and melphalan (140 mg/m2 IV day -1). Autologous stem cell infused on day 0 then Rituximab 1000 mg/m2 on days +1, and +8 post transplantation.

G-CSF 5 mg/kg given daily starting Day 0 till recovery of granulocytes of 4.0 \* 109/L.

Starting dose: 0.4 mCi/kg by vein after Rituxan infusion on Day -14.

Y Zevalin

Imaging dose: 5 mCi by vein following Rituxan infusion on Day -21.

In Zevalin

250 mg/m2 by vein on Day -21 and on Day -14.

1000 mg/m2 by vein on Days +1 and +8.

Rituxan

BCNU

200 mg/m2 by vein every 12 hours on Days -5, -4, -3, and -2.

VP -16

200 mg/m2 by vein every 12 hours on Days -5, -4, -3,and -2.

Ara-C

Stem Cell Infusion

5 mg/kg by vein daily starting Day 0 till recovery of granulocytes of 4.0 x 109/L.

G-CSF

Issa F. Khouri, MD,BS

The goal of this clinical research study is to see if high-dose chemotherapy (BEAM) and rituximab, given together with the new drug 90Y Zevalin, followed by a transplant of blood or marrow stem cells is safe. Another goal is to learn if this treatment can help decrease the chances of the cancer coming back.

BEAM chemotherapy is the standard treatment for lymphoma. BEAM is a combination of chemotherapy drugs (carmustine, cytarabine, etoposide, and melphalan). Rituximab is an antibody made from human and mouse proteins. It reacts with a certain molecule on the surface of lymphoma cells and helps the body's immune system destroy the lymphoma cells. 90Y Zevalin is also an antibody made from mouse proteins. However, it has a particle of radiation attached to it. 90Y Zevalin works by attaching to lymphoma cells, and the radiation particle destroys the lymphoma cell.

For this study, you will receive rituximab by vein followed by a dose of 111In Zevalin by vein (over 15 minutes). 111In Zevalin is different from the study drug (90Y Zevalin). 111In Zevalin has a different type of radioactive particle attached to it. This particle does not kill lymphoma cells, but it can be "seen" inside the body using a special camera (like an x-ray). 111In Zevalin is being used to predict how fast the study drug will travel in the body and how long the drug stays in the body. Doctors need to be able to see how much of the drug goes to the tumor and how much goes to normal organs to determine if it is safe to give 90Y Zevalin on an outpatient basis. A scan will be done as soon as 111In Zevalin is given and about 2-24 hours later. Scans will also be done 2-3 days later. If the radiation in the 111In Zevalin is not a threat to normal organs and bone marrow, you may receive 90Y Zevalin. Seven (7) days after the 111In Zevalin injection, you will receive a second dose of rituximab followed by a dose of 90Y Zevalin by vein (over 15 minutes).

Seven (7) days after the 90Y Zevalin injection, you will receive the BEAM combination of chemotherapy. You will receive carmustine (over 2 hours) on Day 1 of chemotherapy. You will receive cytarabine (over 2 hours) followed by etoposide (over 4 hours) twice a day on Days 2 through 5. On Day 6, you will receive melphalan (over 20 minutes). A catheter (small flexible tube) will be placed in a large vein in your chest so that the chemotherapy drugs can be given to you more easily. This is called a central venous catheter. All of the chemotherapy drugs will be given through the central venous catheter.

One day after finishing the chemotherapy, the stem cells that were collected earlier will be given back to you by vein over about 30 minutes. Starting on the same day, you will receive treatments with G-CSF by injection under the skin once a day. Treatment with G-CSF will continue until your blood counts reach a certain level.

You will receive rituximab by vein (over 6 to 8 hours) on the day after the transplant and again 1-week later.

Blood tests (about 1-2 tablespoons), urine tests, bone marrow collections, and x-rays will be done as needed to track the effects of the transplant. You will have transfusions of blood and platelets as needed. Blood tests (about 1 tablespoon) will be done once a day while you are in the hospital.

Blood tests (about 1-2 tablespoons), urine tests, bone marrow collections, x-rays, CT scans, and PET scans will be done every 3 months for 1 year and then every 6 months for 5 years to check on the status of the disease.

You will be asked to give some extra blood samples (around 1 tablespoon each) at study entry and upon return visits to M. D. Anderson. These samples will be used to test for certain molecules in the blood (HAMA and soluble CD20) and to check on the level of rituximab in the blood.

Treatment will be given in the hospital at the University of Texas (UT) MD Anderson. You will need to stay in the hospital for about 3 to 4 weeks. You should stay in the Houston area for about 2 to 4 weeks after the transplant. After that, you will need to return to Houston from time to time for blood tests, urine tests, and other exams.

This is an investigational study. This is an investigational study. 90Y-Zevalin is approved by the FDA for relapsed and refractory lymphoma. Its use in this trial, however, is investigational. All other drugs used in this study are FDA approved and are commercially available. Up to 60 participants will take part in this study. All will be enrolled at MD Anderson.

Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma

Y Zevalin, BEAM and Rituximab In Autologous Stem Cell Transplantation (ASCT) For Lymphoma

Overall survival reported as number of days participants alive following treatment up to 5 years with annual follow up till disease progression. Evaluations done every 3 months for 1 year and then every 6 months for 5 years to check on the status of the disease, with long-term follow up as needed.

Number of participants alive 3 years following treatment. Evaluations done every 3 months for 1 year and then every 6 months to check on the status of the disease.

Biogen

Rituxan 250 mg/m2 preceding imaging dose of 111In Zevalin (5 mCi); additional infusion 250 mg/m2 Rituxan followed by therapeutic dose of 0.4 mCi/kg 90Y Zevalin received one week after Rituxan/111In Zevalin infusions. One week later, chemotherapy received with BCNU (300 mg/m2, intravenously (IV) day -6) VP-16 (200 mg/m2 IV every 12 hours, days -5 to -2) cytarabine (200 mg/m2 IV every 12 hours, days -5 to -2) and melphalan (140 mg/m2 IV day -1). Autologous stem cell infused on day 0 then Rituximab 1000 mg/m2 on days +1, and +8 post transplantation.

Y Zevalin + BEAM

Issa Khouri, MD / Professor, Stem Cell Transplant

Overall Survival Median

3-Year Overall Survival

Rituxan 250 mg/m2 preceding imaging dose of 111In Zevalin (5 mCi); additional infusion 250 mg/m2 Rituxan followed by therapeutic dose of 0.4 mCi/kg 90Y Zevalin received one week after Rituxan/111In Zevalin infusions. One week later, chemotherapy received with 1,3-bis(2-chloroethyl)-1-nitrosourea bis-chloronitrosourea (BCNU) (300 mg/m2, intravenously (IV) day -6) VP-16 (200 mg/m2 IV every 12 hours, days -5 to -2) cytarabine (200 mg/m2 IV every 12 hours, days -5 to -2) and melphalan (140 mg/m2 IV day -1). Autologous stem cell infused on day 0 then Rituximab 1000 mg/m2 on days +1, and +8 post transplantation.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies	NCT00472056	Lymphoma	Carmustine Etoposide Cytarabine Melphalan Rituximab	- 80 Years	M.D. Anderson Cancer Center
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation	NCT00591630	Diffuse Large C... Lymphoma	Zevalin Carmustine Etoposide Cytarabine Melphalan Rituximab Stem Cell Trans...	18 Years - 70 Years	M.D. Anderson Cancer Center
Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma	NCT01538472	Lymphoma	Y Zevalin In Zevalin Rituxan BCNU VP -16 Ara-C Melphalan Stem Cell Infus... G-CSF	18 Years - 65 Years	M.D. Anderson Cancer Center
Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma	NCT01538472	Lymphoma	Y Zevalin In Zevalin Rituxan BCNU VP -16 Ara-C Melphalan Stem Cell Infus... G-CSF	18 Years - 65 Years	M.D. Anderson Cancer Center

Spots Global Cancer Trial Database for bicnu

Every month we try and update this database with for bicnu cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for bicnu

Every month we try and update this database with for bicnu cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for bicnu cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.